Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 100 clinical trials
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

cell transplantation
Children's National Medical Center
 (5.4 away) Contact site
  • 27 May, 2020
  • +49 other locations
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the …

Children's National Medical Center
 (5.3 away) Contact site
  • 28 Nov, 2020
  • +59 other locations
Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease Type C1

Background For people who have Niemann-Pick disease, type C1 (NPC1), cholesterol and other fats have trouble moving out of liver and other tissue cells. This makes the cells sick. Researchers want to find out if a drug called VTS-270 can help. Objective To test if VTS-270 is safe and effective …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 30 Nov, 2020
  • 1 location
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is a phase Ib standard "3 + 3" design will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with pembrolizumab. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with pembrolizumab, approximately 43 …

Childrens National Research Institute
 (6.0 away) Contact site
  • 13 Aug, 2020
  • +11 other locations
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will …

MedStar Georgetown University Hospital
 (7.8 away) Contact site
  • 01 Jul, 2020
  • +2 other locations
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the …

measurable disease
advanced breast cancer
MedStar Georgetown University Hospital
 (7.9 away) Contact site
  • 10 Sep, 2020
  • +1 other locations
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

This is an open labeled, non-randomized adaptive pilot study. The study interventions involved in this study are: Poly-ICLC (Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, also known as Hiltonol) treatment in combination with anti-PD-1 (Nivolumab, Cemiplimab or Pembrolizumab) or anti-PD-L1 (Atezolizumab or Durvalumab)

Chevy Chase RCCA
 (8.1 away) Contact site
  • 04 Nov, 2019
  • +2 other locations
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors Including Central Nervous System Tumors

Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with everolimus once daily to pediatric participants with recurrent/refractory solid tumors. Phase 2, utilizing …

Children's National Medical Center
 (5.4 away) Contact site
  • 25 Jun, 2020
  • +54 other locations
Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to ongoing checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.

measurable disease
squamous cell carcinoma
head and neck carcinoma
Georgetown University
 (5.8 away) Contact site
  • 18 Oct, 2020
  • +10 other locations
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.

Alkermes Investigational Site
 (7.9 away) Contact site
  • 31 Aug, 2020
  • +9 other locations